Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitochondria | 3 | 2018 | 523 | 0.750 |
Why?
|
| Chlorides | 2 | 2013 | 59 | 0.740 |
Why?
|
| DNA, Mitochondrial | 2 | 2025 | 191 | 0.730 |
Why?
|
| Prostatic Neoplasms | 5 | 2025 | 1092 | 0.730 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 49 | 0.680 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 80 | 0.660 |
Why?
|
| Repressor Proteins | 1 | 2021 | 273 | 0.580 |
Why?
|
| Oxidative Stress | 3 | 2013 | 1003 | 0.520 |
Why?
|
| Manganese Compounds | 2 | 2013 | 15 | 0.460 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 31 | 0.430 |
Why?
|
| Neuroprotective Agents | 2 | 2017 | 269 | 0.420 |
Why?
|
| DNA Breaks, Single-Stranded | 1 | 2013 | 12 | 0.390 |
Why?
|
| Proteome | 1 | 2014 | 152 | 0.390 |
Why?
|
| Manganese Poisoning | 1 | 2013 | 17 | 0.380 |
Why?
|
| Acetylcysteine | 1 | 2013 | 57 | 0.380 |
Why?
|
| Estradiol | 1 | 2014 | 268 | 0.370 |
Why?
|
| Glutathione | 1 | 2013 | 171 | 0.360 |
Why?
|
| Proteomics | 1 | 2014 | 378 | 0.360 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 310 | 0.330 |
Why?
|
| Antioxidants | 2 | 2013 | 443 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 2 | 2025 | 218 | 0.290 |
Why?
|
| Cell Survival | 6 | 2015 | 945 | 0.270 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 1070 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2015 | 1124 | 0.270 |
Why?
|
| DNA Copy Number Variations | 1 | 2025 | 37 | 0.230 |
Why?
|
| Neurons | 1 | 2013 | 1263 | 0.230 |
Why?
|
| Microglia | 2 | 2018 | 208 | 0.220 |
Why?
|
| Manganese | 2 | 2017 | 92 | 0.210 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2025 | 67 | 0.210 |
Why?
|
| Genomics | 1 | 2025 | 293 | 0.190 |
Why?
|
| Male | 10 | 2025 | 23409 | 0.170 |
Why?
|
| Databases, Genetic | 1 | 2021 | 103 | 0.170 |
Why?
|
| Survival Rate | 1 | 2021 | 355 | 0.160 |
Why?
|
| Humans | 13 | 2025 | 43102 | 0.160 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 2676 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2024 | 502 | 0.160 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 239 | 0.150 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 60 | 0.140 |
Why?
|
| Prognosis | 1 | 2021 | 861 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 2853 | 0.140 |
Why?
|
| Hydrolyzable Tannins | 1 | 2018 | 20 | 0.140 |
Why?
|
| Apoptosis | 2 | 2018 | 1568 | 0.140 |
Why?
|
| Environment | 1 | 2018 | 149 | 0.130 |
Why?
|
| Butyric Acid | 1 | 2017 | 19 | 0.130 |
Why?
|
| Excitatory Amino Acid Transporter 1 | 1 | 2017 | 14 | 0.130 |
Why?
|
| Interferon-gamma | 1 | 2018 | 269 | 0.130 |
Why?
|
| Valproic Acid | 1 | 2017 | 21 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 140 | 0.130 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2017 | 33 | 0.130 |
Why?
|
| Contrast Media | 1 | 2017 | 103 | 0.130 |
Why?
|
| Liposomes | 1 | 2017 | 132 | 0.130 |
Why?
|
| Health Status Disparities | 2 | 2014 | 719 | 0.130 |
Why?
|
| Aged | 4 | 2025 | 8214 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 196 | 0.120 |
Why?
|
| Life Style | 1 | 2018 | 334 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 1234 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 532 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2018 | 358 | 0.120 |
Why?
|
| Middle Aged | 5 | 2025 | 12222 | 0.110 |
Why?
|
| Astrocytes | 1 | 2017 | 244 | 0.110 |
Why?
|
| Benzoquinones | 1 | 2015 | 47 | 0.110 |
Why?
|
| Motor Activity | 1 | 2017 | 437 | 0.110 |
Why?
|
| Neoplasms | 2 | 2024 | 1377 | 0.110 |
Why?
|
| Florida | 3 | 2024 | 478 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 587 | 0.100 |
Why?
|
| Young Adult | 3 | 2021 | 5080 | 0.100 |
Why?
|
| Disease | 1 | 2013 | 21 | 0.100 |
Why?
|
| Testosterone | 1 | 2014 | 211 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2013 | 150 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 187 | 0.100 |
Why?
|
| Hydrogen Peroxide | 2 | 2012 | 190 | 0.100 |
Why?
|
| Thymine | 1 | 2013 | 25 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 989 | 0.100 |
Why?
|
| Comet Assay | 1 | 2013 | 77 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 138 | 0.100 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2013 | 83 | 0.090 |
Why?
|
| Adult | 5 | 2025 | 13872 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2013 | 199 | 0.090 |
Why?
|
| DNA Repair | 1 | 2013 | 198 | 0.090 |
Why?
|
| Heme Oxygenase-1 | 1 | 2012 | 52 | 0.090 |
Why?
|
| PC12 Cells | 1 | 2012 | 93 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2013 | 411 | 0.090 |
Why?
|
| Education, Pharmacy | 1 | 2012 | 57 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1271 | 0.090 |
Why?
|
| Lactic Acid | 1 | 2012 | 112 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2012 | 156 | 0.080 |
Why?
|
| Cultural Competency | 1 | 2012 | 138 | 0.080 |
Why?
|
| Students, Pharmacy | 1 | 2012 | 58 | 0.080 |
Why?
|
| Female | 5 | 2025 | 24698 | 0.080 |
Why?
|
| Glucose | 1 | 2012 | 244 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 465 | 0.080 |
Why?
|
| Animals | 7 | 2018 | 16992 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1019 | 0.070 |
Why?
|
| Gene Expression | 1 | 2012 | 701 | 0.070 |
Why?
|
| United States | 4 | 2025 | 5205 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1455 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 704 | 0.070 |
Why?
|
| Oxidopamine | 2 | 2005 | 23 | 0.070 |
Why?
|
| Minority Groups | 2 | 2024 | 690 | 0.070 |
Why?
|
| Time Factors | 1 | 2012 | 1857 | 0.060 |
Why?
|
| Rats | 2 | 2012 | 3735 | 0.060 |
Why?
|
| Mutation | 2 | 2025 | 1177 | 0.060 |
Why?
|
| Leukocytes | 1 | 2025 | 80 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2025 | 95 | 0.060 |
Why?
|
| Smoke | 1 | 2005 | 42 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2005 | 57 | 0.050 |
Why?
|
| Health Behavior | 1 | 2008 | 575 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 135 | 0.050 |
Why?
|
| Neuroglia | 1 | 2005 | 133 | 0.050 |
Why?
|
| Glycolysis | 1 | 2004 | 71 | 0.050 |
Why?
|
| Education, Distance | 1 | 2024 | 46 | 0.050 |
Why?
|
| Research Personnel | 1 | 2024 | 206 | 0.050 |
Why?
|
| California | 1 | 2024 | 548 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1285 | 0.050 |
Why?
|
| Nitrites | 2 | 2015 | 55 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2015 | 128 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2025 | 1759 | 0.040 |
Why?
|
| Universities | 1 | 2024 | 559 | 0.040 |
Why?
|
| Mice | 3 | 2018 | 6644 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 28 | 0.030 |
Why?
|
| Smoking | 1 | 2005 | 1024 | 0.030 |
Why?
|
| Viscosity | 1 | 2017 | 46 | 0.030 |
Why?
|
| Gadolinium | 1 | 2017 | 30 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 95 | 0.030 |
Why?
|
| Rotarod Performance Test | 1 | 2017 | 14 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 129 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2017 | 38 | 0.030 |
Why?
|
| Cerebellum | 1 | 2017 | 79 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2017 | 141 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 272 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 408 | 0.030 |
Why?
|
| Students | 1 | 2021 | 626 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2015 | 95 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 306 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 277 | 0.030 |
Why?
|
| Lysine | 1 | 2015 | 119 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 1410 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 49 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 249 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 712 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 458 | 0.030 |
Why?
|
| Magnesium | 1 | 2013 | 94 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 458 | 0.020 |
Why?
|
| Health Surveys | 1 | 2014 | 405 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 352 | 0.020 |
Why?
|
| Schools, Pharmacy | 1 | 2012 | 19 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 3156 | 0.020 |
Why?
|
| Awareness | 1 | 2012 | 73 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 1869 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2017 | 460 | 0.020 |
Why?
|
| Professional-Patient Relations | 1 | 2012 | 60 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 128 | 0.020 |
Why?
|
| Prejudice | 1 | 2012 | 116 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 678 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 780 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2012 | 193 | 0.020 |
Why?
|
| Language | 1 | 2012 | 185 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 231 | 0.020 |
Why?
|
| Curriculum | 1 | 2012 | 318 | 0.020 |
Why?
|
| Nigeria | 1 | 2008 | 92 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2008 | 158 | 0.020 |
Why?
|
| Child | 1 | 2014 | 3443 | 0.020 |
Why?
|
| Sympatholytics | 1 | 2005 | 13 | 0.010 |
Why?
|
| Oxidants | 1 | 2005 | 42 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 2005 | 37 | 0.010 |
Why?
|
| Pyridinium Compounds | 1 | 2005 | 29 | 0.010 |
Why?
|
| Cell Respiration | 1 | 2004 | 35 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 541 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2005 | 136 | 0.010 |
Why?
|
| Glioma | 1 | 2005 | 96 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 6081 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 457 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 883 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2005 | 386 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 3994 | 0.010 |
Why?
|